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Summary
Objective: A new micro-histological method of assessing the sulfated glycosaminoglycan (S-GAG) content in unstained histological sections
of articular cartilage was developed and used to study the effects of orally administered Diacerhein (DIA) on joint cartilage in an ovine model
of osteoarthritis (OA).
Methods: Twenty adult, age-matched Merino wethers were subjected to bilateral lateral meniscectomy, while 10 served as non-operated
controls (NOC groups). Half of the operated sheep (N=10) remained untreated (MEN groups), while the other 10 animals were given DIA
(25 mg/kg orally) daily for 3 months, then 50 mg/kg daily for a further 6 months (DIA groups). Five animals each of the DIA, MEN and NOC
groups, respectively, were sacrificed at 3 months post-operatively, and the remainder 6 months later. For the present study only one knee
joint of each animal was used for histological processing. The tissues studied were from the lateral femoral condyles (LFC) and lateral tibial
plateaux (LTP). Each of these joint regions was further subdivided into inner (I), middle (M), and outer (O) zones. Unstained histological
sections from these AC regions and zones were then analysed for S-GAG content using the following procedure. Images of each section of
6 m thickness were acquired using a flatbed scanner and the area determined with an image analysis software program. The sections were
then transferred to wells of a microtiter plate, digested with papain and the S-GAG content quantitated using a modification of the
1,9-dimethylmethylene blue dye binding assay. The data was represented as g S-GAG/mm3 of each tissue section. These data were also
compared with toluidine blue stained sections from the same paraffin blocks.
Results: The results obtained showed that the area of histological sections could be very accurately determined by computer assisted image
analysis using a 10 mm×10 mm calibration grid. Cartilage sections of areas ranging from 1 mm2 up to 25 mm2 were analysed for S-GAG
content with this simple technique. There was a linear relationship between section thickness (2–10 m) and S-GAG content per unit area
(R2=0.993). Sections of 6 m thickness were found to be optimal. S-GAG analyses of serial sections from tibial and femoral articular
cartilage (I, M and O zones) revealed an average coefficient of variation of 7.0±2.3% (range 4.9–10.2%) confirming the accuracy and
reproducibility of this assay method. A separate experiment showed that no significant losses of S-GAG occurred during the histological
sample processing.
The different regions and zones of the knee joint AC in the six experimental groups revealed variable levels of S-GAG which did not
necessarily correlate with the histochemical distribution of toluidine blue staining. The major S-GAG changes occurred in the middle (lesion
zone) and outer zones (hypertrophic zone) of both the LFC and LTP of the MEN groups. In the lesion (M) zone the S-GAG content was
reduced while in the O zone levels were increased at both 3 and 6 months post-surgery. In animals receiving Diacerhein S-GAG levels in
the M zone were lower than or equivalent to those of non-drug treated OA or non-operated controls for both joint regions at 3 and 6 months.
While the hypertrophic response in the outer zone of the LFC, as assessed by S-GAG content, was enhanced by drug treatment, the
cartilage of the outer zones of the LTP was not affected by drug treatment.
Conclusion: The results of this study have demonstrated that the S-GAG (and therefore proteoglycan [PG]) content in different cartilage
zones of OA joints can be readily quantitated by direct biochemical analysis of unstained histological sections. By this means subtle changes
in PG distribution in different cartilage zones, which were not evident using traditional histochemical staining methods, could be readily
detected. © 2001 OsteoArthritis Research Society International
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Osteoarthritis (OA) is a multifactorial disorder in which
pathological changes become manifest in articular carti-
lage, synovium and subchondral bone1–3 leading to pain
and loss of joint function. In the past, pharmacological
intervention in OA has been largely confined to analgesics,
steroidal or non-steroidal anti-inflammatory drugs. While
these agents have provided an important means of control-
ling the inflammation and pain in OA, their application has
been overshadowed by their deleterious side effects on
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ANIMALS AND SURGICAL PROTOCOL
Thirty adult (2–3 years old) pure bred Merino wethers
obtained from the University of Sydney farm at Camden,
NSW (Department of Veterinary Clinical Sciences), were
used for this study. The animals were divided into age- and
weight-matched groups. Ten of these animals served as
non-operated normal controls (NOC), while 20 underwent
bilateral lateral meniscectomy of the stifle joints using a
procedure described previously24. All animals were allowed
to recover for 2 weeks in the animal house. The surgical
procedures and the programs of the post-operative care
were approved by the Animal Care and Ethics Committee
of the University of Sydney (ACEC No N07/2-94/3/943).
Ten of the operated sheep were used as non-drug-
treated OA controls (MEN), while the remaining 10 menis-
cectomized animals were given Diacerhein (DIA) using a
protocol as described below. After the post-operative recov-
ery period of 2 weeks and during drug treatment all animals
were maintained in an open, grassed paddock (100 m×
22 m) with supplementary hay feeding and water ad libitum
for the duration of the study.DRUG ADMINISTRATION
A weighed amount of pharmaceutical grade Diacerhein
powder (Negma Laboratories, Paris, France) was stirred
with 2.5% of methylcellulose in water in a ceramic mortar
until the suspension became homogenous. A predeter-
mined volume of this methylcellulose suspension of the
drug corresponding to the required dose was administered
to the DIA groups commencing 2 weeks after the last
operation. The non-drug-treated groups (MEN groups)
received an equivalent volume of aqueous methylcellulose.
Both the 3 month and 9 month DIA-treated groups received
25 mg/kg of the drug daily for the first 3 months; there-
after the 9 month DIA group received 50 mg/kg DIA daily
for the remaining 6 month period. The treatment regimen
used in this study was designed with the advice of
Negma Laboratories, Paris, France and described by Hwa
38et al.PROCESSING OF SPECIMENS
At the end of the 3 and 9 month experimental period, all
animals were euthanased by an intravenous overdose of
sodium pentobarbitone (Lethabarb®, Virbac, Sydney, NSW,
Australia). The stifle joints were removed intact and im-
mediately transferred to the laboratory on ice. After remov-
ing the periarticular soft tissues, the joints were opened and
mid-coronal bone slabs (3–4 mm thickness) were cut
through the central weight-bearing region of the tibial
plateaux and the femoral condyles with a band saw to
obtain full-width medial and lateral osteochondral sections
of 1.0 cm depth. The slabs were defined as regions of the
lateral femoral condyle (LFC), and lateral tibial plateau
(LTP).cartilage4,5 and the gastrointestinal tract6–8. More recently
drugs are being developed which purport to provide symp-
tomatic relief by targeting the pathology of OA, particularly
in cartilage and subchondral bone. Such agents have
been classified as structural modifying steoarthritis drugs
(SMOADs)9 and would be expected to retard, stabilize or
reverse the pathological changes which occur in OA joints,
thereby limiting disease progression. Since detectable
structural joint changes in human OA generally take several
decades to develop and techniques to evaluate these
changes are still under investigation, animal models of OA
have been widely used to evaluate potential SMOADs and
to study their mechanisms of action10–13.
Total or partial meniscectomy is a very common ortho-
pedic procedure which frequently leads to cartilage
degeneration and the onset of OA. A contributing factor to
these deleterious joint changes is the high focal stresses
imposed on articular cartilage following the excision of
the meniscus14–16. Previous studies in dogs17–19 and
sheep20–25 have established that similar events occurred in
joints of these animal species following meniscectomy.
Indeed, the biochemical and histological changes which
occurred in cartilage and subchondral bone following bi-
lateral meniscectomy in sheep were shown to exhibit many
similarities to early human OA24–26. Moreover, using the
ovine model the topographical variation which exists in both
the quantitative and qualitative distribution of proteoglycans
(PG) in articular cartilage of different joint regions has been
identified24,26.
Diacerhein (DIA) is a slow-acting drug for OA which has
been reported to provide symptomatic relief when adminis-
tered orally to patients with OA of the hip27. The drug has
also been observed to inhibit the production of interleukin-1
(IL-1) and reduced cartilage breakdown in a murine granu-
loma model28, and to attenuate the development of
cartilage lesions in dog29 and rabbit models of joint
arthropathy30. In-vitro studies have shown that DIA inhib-
ited collagenase production by lapine chondrocytes and
modulated IL-1 inhibition of PG synthesis31,32. A recent
study also suggested that DIA enhanced the expression of
transforming growth factor (TGF)-1 and 2 in articular
chondrocytes33. Collectively, these reports suggest that
DIA could be classified as a SMOAD at least with respect to
its effects on cartilage in animal models.
The histological grading system of articular cartilage
used by Mankin et al.34 and its subsequent modifi-
cations3,5,21,24 have provided a useful means of assessing
the loss of PG and the severity of AC lesions in OA joints
but are limited by the inability of histochemical stains to
detect small changes in PG content as may occur in early
OA35. More precise methods for the determination of PG
concentrations in articular cartilage36 and intervertebral
disc histological sections37 have been reported using
safranin-O staining and subsequent microspectro-
photometric quantitation of glycosaminoglycans in these
sections. However, these methods require the use of
specialized spectroscopic equipment to quantitate the
intensity of light transmitted through stained sections. In
order to overcome these difficulties and to provide a direct,
analytical means of cartilage assessment we have
developed a simple method to quantitate the sulfated
glycosaminoglycan content (S-GAG) in unstained histologi-
cal sections of AC. This procedure was then used to
determine the S-GAG content of AC in different regions and
zones of joints from animals with surgically induced OA
which had been treated orally with Diacerhein for 3 or 6
months. The data obtained was compared with the S-GAGcontent of corresponding regions of AC of non-drug-treated
OA and non-operated control animals in an attempt to
evaluate the ability of Diacerhein to influence the S-GAG
content in different topographical regions and zones of OA
joints.
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neutral buffered formalin and were fixed for 48 h at room
temperature. The samples were then decalcified in 10%
(v/v) formic acid, 5% (v/v) formalin for 7 days with continu-
ous agitation, followed by rinsing with running tap water
(30 min) and dehydration through a series of graded etha-
nol solutions (70%, 95% and 100% (v/v)), infiltrated in
methylbenzoate/celloidin and finally embedded in paraffin.
Sections were then cut and mounted on glass slides, using
standard histological procedures. Four micrometer sections
were also stained with toluidine blue to illustrate the histo-
logical appearance of the different articular cartilages.
A separate experiment was conducted to ascertain that
the histological processing did not cause significant losses
of S-GAG from the tissues. For this purpose, 3 mm diam-
eter full-depth cartilage plugs were cut from the middle
zone of femoral condyles of two non-operated joints as
illustrated in Fig. 1. Two pairs of adjacent plugs obtained
from the anterior and posterior part of the joint were either
processed for histology as outlined above or freeze-dried
and stored dry until analysis. The processed samples were
then deparaffinized, taken to water and the S-GAG content
determined as described below. The moisture content
of the articular cartilages was determined by weighing
all samples at the appropriate steps of the respective
procedures. This permitted two sets of water content to be
determined for the processed samples because the wet
weight was assessed at the initial tissue harvest and at the
point after deparaffinizing before drying.
The repeatability of the assay was assessed using 20
serial sections of tibial and femoral articular cartilage from
one non-operated control animal as described below.
Serial sections of increasing thickness from 2 m to
10 m were also prepared and analysed in triplicate in
order to determine the linearity of the assay and the optimal
section thickness.Fig. 1. Diagrammatic representation of an ovine distal femur
showing the locations where 3 mm diameter full-depth plugs
of condylar articular cartilage were sampled for analysis of
moisture content and S-GAG content directly and after histological
processing.Fig. 2. Digitized scan of an unstained histological section of an
ovine lateral tibial plateau (LTP) showing the sequence of sample
preparation. (A) Intact unstained section of LTP. (B) Same section
with subchondral bone partially removed. (C) Same section with
subchondral bone completely removed and subdivided into inner
(I), middle (M) and outer (O) zones, ready for area quantitation and
S-GAG determination. Magnification bar represents 10 mm.ARTICULAR CARTILAGE SAMPLE PREPARATION FOR ROUTINE
S-GAG DETERMINATION
Unstained coronal sections (6 m thick) of the lateral
compartment of sheep knee joint tissues were deparaffin-
ized, taken to water and air dried. A dissecting microscopeat 15× magnification was used for the sample preparation
and tissue transfer. The subchondral bone tissue was
removed with a no. 11 scalpel blade after scoring along the
cartilage–bone interface. The remaining articular cartilage
was further divided into three equal lengths and a thin strip
of tissue removed perpendicular to the articular surface.
These three zones corresponded to the area nearest to the
insertion of the cruciate ligaments (inner zone, I), across
the middle (middle zone, M) to the outermost cartilage area
(outer zone, O), respectively. Anatomically, the location of
the O zone of the tibial plateau was normally fully covered
(or protected) by the meniscus, the M zone was partially
covered and the I zone was totally exposed. Figure 2
shows a scan of a tibial plateau section, illustrating the
sequence of sample preparation for the determination of
S-GAG, including the removal of the subchondral bone
tissue and the arbitrary division of the AC into thirds of I, M
and O zones. The glass slide containing the prepared
cartilage section was then scanned on an AVR flatbed
scanner (AVR Technology, Inc., San Jose, CA, U.S.A.) with
an appropriate dark background for enhanced contrast.
Alternatively, an image of the sections was captured with a
Pixera ProfessionalY digital camera system and software
(Pixera Corporation, Cupertino, CA, U.S.A.). A 10 mm by
10 mm microscope eyepiece graticule was also scanned
(or an image captured) and used as the standard for area
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pixels into area units, i.e. mm2. The scans were stored as
compressed JPEG files and the areas quantitated (in
triplicate) using an image analysis program (Image Pro®
Plus, Version 3.0, Media Cybernetics, Silver Spring, MD,
U.S.A.). The glass slide with the area/volume quantitated
sections was briefly dipped in water to wet and soften the
articular cartilage for removal and transfer. The individual
zones were then carefully peeled off the wet surface with
the tip of a no. 11 scalpel blade and placed into a well of a
96-well microtiter plate containing 50 l papain digestion
buffer. Duplicate sections were thus prepared, digested and
analysed.PAPAIN DIGESTION
The papain digestion buffer consisted of 2 l papain
suspension (Sigma P-3125) per milliliter of calcium and
magnesium free phosphate buffered saline containing
5 mM cysteine (Sigma Chemical Co., St Louis, MO, U.S.A.)
and 10 mM EDTA, pH 7.4. Each plate contained a series
(0–5 g/well) of chondroitin sulfate (CS) (Sigma C-8529)
standards prepared from working solutions (100 g CS/ml)
in identical papain digestion buffer. The plates were then
covered with a self-adhesive plate sealer and incubated
within a humidified container in a 60°C oven for 16 h. After
reaching room temperature the plates were centrifuged for
5 min at 1500 g with the plate sealer in place to collect
condensation droplets. The cartilage plugs prepared for the
assessment of potential S-GAG losses during processing
were similarly digested in 1.0 ml papain buffer together with
a separate CS standard (100 g/ml) prepared in papain
buffer. Appropriate dilutions were made for the subsequentS-GAG quantitation using the dimethylmethylene blue
binding assay in microtiter plates.1,9-DIMETHYLMETHYLENE BLUE BINDING ASSAY
1,9-Dimethylmethylene blue (DMMB) (Aldrich 34,108-8,
Sigma-Aldrich, Castle Hill, NSW) solutions (50 mg/l) was
prepared by dissolving 50 mg of DMMB in 5 ml of ethanol
and subsequent dilution to a volume of 1000 ml with 0.2%
(w/v) sodium formate buffer, pH 3.5.
Using an electronic multi-channel pipette 150 l of
DMMB reagent was rapidly added to each well containing
the digested cartilage sample. The plate was briefly mixed
on a plate shaker (5–10 s) and the absorbance at 650 nm
measured immediately in a plate reader. The GAG content
was calculated from the standard curve constructed by
the plate reader software (Softmax®, Molecular Devices
Corporation, Menlo Park, CA, U.S.A.).DATA ANALYSIS AND STATISTICS
All data were entered into a spreadsheet and the subse-
quent calculations and statistical analyses [ANOVA with a
Fisher’s PLSD (protected least significant difference) post-
hoc treatment] were performed using a statistical software
package (StatView®, Version 5.0, Abacus Concepts, Inc,
Berkeley, CA, U.S.A.). The threshold value for significance
was set to 0.05.Fig. 3. Toluidine blue stained sections representative of the lateral femoral condyles (LFC) and lateral tibial plateaux (LTP) from all three
treatment groups. Note the toluidin blue staining of the proteoglycans which shows little variation between zones. Lesions are indicated by
‘L’ and osteophyte formation by arrowheads in the operated groups. Magnification bar represents 10 mm.Results
Representative sections of the lateral femoral condyles
and tibial plateaux from all three groups with lesions and
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of articular cartilage and the sulfated glycosaminoglycan (S-GAG)
content per unit area determined as described in Methods.Fig. 5. Box plot of S-GAG content of 20 serial sections of the lateral
femoral condyle (LFC) and tibial plateau (LTP), divided into the
three different zones [inner (I), middle (M), and outer (O)] from
a nonoperated control sample illustrating the repeatability of the
assay.osteophytes identified are shown in Fig. 3. From this figure
it is evident that the toluidine blue histochemical staining of
sections did not reflect the true variation in S-GAG content,
as determined using the present method (see results
below). This difference was most marked in the outer zone
of the meniscectomized group where the S-GAG content
was increased but staining appeared normal. The areas of
coronal AC sections from sheep stifle joints ranged
between 2–10 mm2 (corresponding to values of 0.012–
0.06 mm3) and could be very accurately determined by
image analysis using the calibrated graticule as a standard
area. A clear linear relationship (R2=0.993) between sec-
tion thickness and sulfated GAG content per unit area was
demonstrated as illustrated in Fig. 4. A tissue section
thickness of 6 m (verified by digital micrometer) was found
to be optimal and was used for all subsequent analyses
of sections. The results could were therefore expressed as
micrograms S-GAG per cubic millimeter of tissue (g/mm3).
The modified 1,9-dimethylmethylene blue (DMMB)
dye binding assay used here was adapted from the
method originally described by Farndale et al.39,40 and
Templeton41. However, it was modified and improved to
provide for the greatly extended working range required of
this assay. The absorbance measurement of the band
of uncomplexed DMMB at 650 nm, rather than the -band
of the S-GAG-DMMB complex at 535 nm, resulted in a
two-fold increase in sensitivity. In addition, by varying the
DMMB concentration (10 mg/l to 500 mg/l), we were able to
determine S-GAG levels over a 500-fold range from 0.1 g
to 50 g per well (results not shown).
Figure 5 and Table I show the results of a validation
study to demonstrate the repeatability of the assay. Twenty
serial sections (assayed in triplicate) of the lateral femoral
condyle and lateral tibial plateau cartilages from a non-
operated control joint were used. It is evident that the
coefficients of variation ranged from 4.9% to 10.2%, which
we considered were acceptable for the purpose of this
assay and the present comparative study.
Table II provides data which showed that the tissue
processing protocol used did not generally affect the
S-GAG levels measured in articular cartilage. Except forone region (anterior LFC), insignificant differences were
found between adjacent cartilage plugs which were ana-
lysed for S-GAG either with or without histological process-
ing. Furthermore both methods detected the normal
topographical variations in S-GAG content between the
anterior and posterior joint regions. It was also evident that
the moisture content of all samples, irrespective of their
origin (MFC, LFC, left or right), were within a very narrow
range averaging 69.1±1.8% (mean±S.D.) for the un-
processed control samples. The wet weight of the pro-
cessed samples was determined twice for each sample;
first at tissue harvest and then at the penultimate step of
the deparaffinizing procedure, before drying. The two
resultant assessments of moisture content of these pro-
cessed samples correlated very closely at 71.8±1.7% and
73.1±2.1%. Although the difference in moisture content
between processed and unprocessed cartilage was small,
it reached statistical significance (P<0.05).
The results of the S-GAG analysis of articular cartilage
from the three treatment groups, using the new technique,
are summarized in Figs 6 and 7. In Fig. 6 the levels of
S-GAG for the femoral condyles are represented with
regard to cartilage zones (I,M,O) for each treatment group
thus facilitating comparisons of S-GAG between zones
[Fig. 6(A) and (B)], as well as for each zone to enable
comparisons for all experimental groups to be readily made
[Fig. 6(C) and (D)]. Figure 7 shows the data for the
corresponding lateral tibial cartilages. In both Figs 6 and 7,
(A) and (C) represent the 3 months and (B) and (D) the
9 month experimental period, respectively.
In the non-operated control groups (NOC) there were
highly significant differences between the S-GAG content
of the I, M and O zones of both the LFC and LTP. The outer
zone of the NOC, which is covered by the lateral meniscus,
contained approximately half the S-GAG content of the
middle and inner zones [Fig. 6(A),(B) and 7(A),(B)].
Three or 9 months after lateral meniscectomy (MEN) the
S-GAG levels were progressively increased in the O zones,
particularly in the LTP after 9 months [Fig. 7(D)]. At the
same time there was a corresponding decrease in S-GAG
levels in all the M zones (which included the main lesion)
compared to those of the NOC groups, especially in the
LFC after 9 months [Fig. 6(D)]. As a result, there was no
Osteoarthritis and Cartilage Vol. 9 No. 3 243significant difference in S-GAG content in the meniscect-
omized group between the O and M zones of the LFC and
LTP after 9 months [Fig. 6(B) and 7(B)].
DIA treatment further increased the S-GAG content of
the O zone of the LFC after 3 and 9 months compared to
NOC and MEN groups but had no significant effect on the
O zone of the LTP compared with the MEN group [Fig. 7(C)
and (D)]. In the M zone of both LFC and LTP of the DIA
treated animals the S-GAG content was lower than in the
MEN group after 3 months but only in the LTP after 9
months [Fig. 6(C),(D) and 7(C),(D)].
There were minimal changes in the S-GAG content of
the inner (I) zones of the treated groups except that the DIA
treatment decreased the S-GAG levels in the LTP after
three months [Fig. 7(C)] and increased it in the LFC after
nine months relative to NOC [Fig. 6(D)]Table I
Repeatability of the assay
Joint region
and zone
Number
(N)
Mean
(g S-GAG/mm3)
S.D. S.E. CV
LFC—inner 60 41.5 2.7 0.35 6.5%
LFC—middle 60 58.1 2.8 0.37 4.9%
LFC—outer 60 37.6 3.6 0.46 9.5%
LTP—inner 60 39.7 2.2 0.28 5.5%
LTP—middle 60 46.5 2.4 0.31 5.2%
LTP—outer 60 25.8 2.6 0.34 10.2%
Sulfated glycosaminoglycan (S-GAG) content of 20 serial sections of zones (inner, middle and outer) from the
lateral femoral condyle (LFC) and tibial plateau (LTP) of a nonoperated control sample analysed in triplicate using
the method described in the text, showing the number of data points (N), mean, standard deviation, standard
error, and coefficients of variation.Table II
Comparison of sulfated glycosaminoglycan (S-GAG) content of unprocessed articular cartilage and samples
processed for histological assessment
Joint
region
Left/
right
Anterior/
posterior
Unprocessed* Processed† P-value
(processed vs
unprocessed)Mean±S.D.(g S-GAG/mg
dry tissue)
Mean±S.D.
(g S-GAG/mg
dry tissue)
LFC‡ Left Anterior 168±4.3 148±5.5 0.01
LFC Left Posterior 172±4.0 170±4.0 0.61
LFC Right Anterior 159±8.5 154±3.0 0.37
LFC Right Posterior 190±3.2 192±6.2 0.60
MFC§ Left Anterior 143±2.3 142±7.6 0.78
MFC Left Posterior 207±2.5 202±2.5 0.10
MFC Right Anterior 118±2.5 123±6.0 0.23
MFC Right Posterior 244±1.7 246±8.6 0.67
*Determined by direct analysis using the modified DMMB binding assay.
†After processing for histology and deparaffinized.
‡Lateral femoral condyle cartilage.
§Medial femoral condyle cartilage.
The value for significance was set to 0.05.Discussion
The methodology described in this study was dependent
on the accurate determination of the physical dimensions
of unstained histological sections. This was achieved by
digital scanning techniques and subsequent computer
assisted image analysis. In addition, the thickness (6 m)of the cartilage sections was verified by repeated random
measurements with a digital micrometer. The study also
confirmed that the modification of the DMMB assay
employed to improve its sensitivity and the use of the same
microtiter wells for both the cartilage digestion and the
quantitation of S-GAG content in tissue micro-sections
provided a convenient and rapid method of analysis.
Methodical errors due to sample dilutions or transfers were
thus eliminated or kept to a minimum.
The question of whether proteoglycans (and therefore
S-GAGs) were lost from cartilage sections during histologi-
cal processing was also addressed in this study. Analysis of
adjacent cartilage plugs with and without processing con-
firmed that losses were small. One region (anterior LFC)
did show a difference between methods but the reasons for
this are unclear and appear to be the exception rather than
the rule. Moreover, since all sections were treated identi-
cally, the losses which did occur would be of a systematic
nature allowing meaningful comparisons between treat-
ments to be determined.
The S-GAG levels in the outer zones of the LFC or LTP
regions of the non-operated control joint cartilages were
significantly lower than in adjacent middle and inner zones.
This difference arises from the reduced mechanical loading
244 D. Burkhardt et al.: A new assay for GAG in cartilage sections: effects of DiacerheinFig. 6. Sulfated glycosaminoglycan (GAG) content of inner (I), middle (M) and outer (O) zones of articular cartilage from the lateral femoral
condyles (LFC) of ovine stifle joints from the 3 and 9 month experimental periods. (A) and (C) represent the 3 month and (B) and (D) the 9
month experimental period, respectively. GAG levels are expressed as g/mm3 using chondroitin sulfate as a standard. (A) and (B) Arranged
by treatment groups (DIA, MEN, NOC); each group is split by zone (I,M,O) to illustrate changes occurring in different zones within a particular
treatment group. (C) and (D) Arranged by zone, (I,M,O); each zone is split by treatment (DIA, MEN, NOC) to illustrate changes occurring due
to treatment within a particular zone. *Indicates P<0.05; **indicates P<0.005; ***indicates P<0.0005.due to the overlying meniscus which normally distributes up
to 50% of the load across the joint2–6. When these same
three cartilage zones were examined using traditional
histochemical staining with toluidine blue, uniform staining
intensity across the whole section was observed, demon-
strating the limited sensitivity of such dyes to quantitate
S-GAG concentration in histological sections. Similar
observations have been reported by Ostergaard et al.35
using safranin-O staining of human cartilage sections.
As has been noted previously26,38,47, lateral meniscec-
tomy, while producing high focal stress and cartilage
degeneration in the middle zone of the tibial plateau also
initiated an anabolic (hypertrophic) response by chondro-
cytes in the outer zones as identified by the increased PG
content in these areas. This hypertrophic response of
chondrocytes in the outer zone of the LFC of meniscect-
omized ovine joints was further enhanced in the Diacerhein
treatment group. The explanation for the increased ana-
bolic response of the chondrocytes in the outer zones of
joints of the Diacerhein-treated meniscectomized animals
is not entirely clear, but may be a result of up-regulation
of TGF- expression by chondrocytes exposed to this
drug32,33. While TGF- is known to increase the synthesis
of PG by articular cartilage in vitro48 its injection into murine
knee joints stimulates osteophytosis49,50 which alsooccurred in the outer zones of meniscectomized joints in
this study.
As reported previously24,38,47, it is the M zone of the
femoral and tibial cartilages where the classical pathologi-
cal lesions of early OA, such as softening and cartilage
erosion, are first evident. The corresponding loss of S-GAG
and thus PG content from these zones therefore reflects
the increased catabolic activity in these areas. This loss
of S-GAGs from the M zone was more pronounced in the
DIA treated groups than non-drug-treated control. While
the reasons for this enhancement are still to be deter-
mined, and are contrary to previous reports using other
models29–30, it could be speculated that increased weight
bearing due to decreased pain could be a contributory
factor. Diacerhein does exhibit antiinflammatory activity
and diminishes the pain associated with osteoarthritis27–28.
O’Connor et al.51 have shown that reducing the physiologi-
cal protective effects on anterior cruciate ligament deficient
canine joints by dorsal route ganglionectomy can acceler-
ate progression of osteoarthritic lesions. The possibility of
increased weight bearing activity in meniscectomized ani-
mals receiving DIA might also account for the elevated
hypertrophic response of cartilages and increase in
subchondral bone thickness in the outer zones of their
joints47.
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The determination of the sulfated glycosaminoglycan
content in unstained histological sections as described
here offers a sensitive and reproducible technique for
monitoring subtle changes in articular cartilage PG metab-
olism in arthritic joints. This quantitative technique offers
several advantages over the non-parametric histochemical
staining methods which have been traditionally used to
assess the levels and distribution of proteoglycans in
articular cartilage sections.
Using this technique it was shown that Diacerhein, when
given orally to meniscectomized sheep for 3 and 9 months,
induced significant changes in the S-GAG composition of
the outer and middle zones of articular cartilage from
the OA joints. Diacerhein treatment increased the S-GAG
levels in the outer zones of joint AC whereas levels in the
lesion (middle) zone were reduced relative to non-drug-
treated controls. Whether these cartilage changes
occurred from a direct effect of high dose Diacerhein on
chondrocyte metabolism or arose because of increased
weight bearing of the meniscectomized joint remains to
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to treatment within a particular zone. *Indicates P<0.05; **indicates P<0.005; ***indicates P<0.0005.References
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